Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Puerto Rico Healthcare Daily.
Press releases published on May 12, 2025
Catheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic Alliance
GlobeNewswire
·
May 12, 2025
Fort Mill, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced that it has …
Scientific Industries to Host First Quarter Fiscal Year 2025 Financial Results Investor Call on May 14, 2025
GlobeNewswire
·
May 12, 2025
BOHEMIA, N.Y., May 12, 2025 (GLOBE NEWSWIRE) -- Scientific Industries, Inc. (OTCQB: SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced it will file a Form 10Q and issue a press release after the …
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
GlobeNewswire
·
May 12, 2025
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May …
Quipt Home Medical Reports Fiscal Second Quarter 2025 Results
GlobeNewswire
·
May 12, 2025
CINCINNATI, May 12, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fiscal second quarter 2025 …
New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
GlobeNewswire
·
May 12, 2025
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide …
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 12, 2025
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context …
ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress
GlobeNewswire
·
May 12, 2025
KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD). Obesity-associated cardiometabolic preclinical …
Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX- …
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire
·
May 12, 2025
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and …
Vireo Growth Inc. Announces Closing of WholesomeCo Cannabis & Arches Merger Transactions
GlobeNewswire
·
May 12, 2025
– Acquisitions strengthen profitability and competitive position with proprietary technology platform – – Missouri and Nevada transactions remain on track to close during the second quarter of 2025 – MINNEAPOLIS, May 12, 2025 (GLOBE NEWSWIRE) -- Vireo …
Cellectis Reports Financial Results for the First Quarter 2025
GlobeNewswire
·
May 12, 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …
Editas Medicine Announces First Quarter 2025 Results and Business Updates
GlobeNewswire
·
May 12, 2025
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo …
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
GlobeNewswire
·
May 12, 2025
FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a …
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b …
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 12, 2025
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on the accelerated pathway are expected in …
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European …
Maravai Lifesciences Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first …
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025 Cash, …
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 12, 2025
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise …